An audit demonstrating a reduction in MRSA infection in a specialised vascular unit resulting from a change in infection control protocol.
BACKGROUND
In 2003, 18% of all admissions to our vascular ward were colonised by MRSA, with an MRSA infection rate of 10.6%. Standard practice was to segregate patients with proven MRSA from the rest of the patient pool. After a prospective audit, regression analysis was used to identify factors that could stratify patients into high and low risk for MRSA colonisation. A change in isolation policy was introduced that segregated patients according to their risk of MRSA acquisition, and isolated all patients undergoing prosthetic vascular reconstruction. Antibiotic policy was also altered. This audit reports the impact of these changes on MRSA colonisation and infection rates.


METHODS
The MRSA status of patients during 777 in-patient episodes was prospectively recorded during three time spans; period 1 (November 2002-April 2003) before the change in isolation and antibiotic policy and, periods 2 (August-December 2003) and 3 (October 2004-January 2005) after the change in policy.


RESULTS
Hospital acquired MRSA colonisation was reduced from 10.6% in period 1, to 1.1 and 1.4% in periods 2 and 3, respectively (p<0.001). Similarly, MRSA infection rates fell from 10.6 to 2.9 and 0.9% over the same time frame (p<0.001). The most dramatic changes in MRSA infection rates occurred in patients undergoing aneurysm repair (MRSA infection 30.1% in period 1 vs. 3.9 and 2.9% in periods 2 and 3) and lower limb revascularization (31 vs. 0 vs. 4.2%). Stepwise regression analysis revealed that the system of isolation was a significant factor reducing MRSA infection and colonisation rates (p<0.001).


CONCLUSIONS
These data demonstrate that a change in infection control policy can significantly reduce MRSA infection in a vascular unit.
Thompson
M
M
Department of Vascular Surgery, St George's Hospital, London, UK. matt.thompson@stgeorges.nhs.uk
D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D002353:Carrier State / Q000517:prevention & control; D003428:Cross Infection / Q000517:prevention & control* / Q000635:transmission; D006757:Hospital Units; D006801:Humans; D017053:Infection Control / Q000379:methods*; D008485:Medical Audit; D016106:Methicillin Resistance; D010356:Patient Isolation; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000517:prevention & control* / Q000635:transmission; D013211:Staphylococcus aureus / Q000302:isolation & purification; D013530:Surgical Wound Infection / Q000517:prevention & control* / Q000635:transmission; D014640:Vancomycin / Q000627:therapeutic use*; D014656:Vascular Surgical Procedures
D014640:Vancomycin; D019980:Amoxicillin-Potassium Clavulanate Combination